31 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Takeda California
Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.
Takeda California
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Takeda California
Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors.
Takeda California
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Takeda California
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
Takeda California
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.
Takeda California
Fragment-based drug discovery of potent and selective MKK3/6 inhibitors.
Takeda California
Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Takeda California
A fragment-based approach to identifying S-adenosyl-l-methionine -competitive inhibitors of catechol O-methyl transferase (COMT).
Takeda California
Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.
Takeda California
Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Takeda California
Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.
Takeda California
Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.
Takeda California
Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
Takeda California
Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity.
Takeda California
Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Takeda California
Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
Takeda California
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Takeda California
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
Takeda California
Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.
Takeda California
Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.
Takeda California
Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
Takeda California
1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.
Takeda California